Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
709,2 EUR | -0,70% | -0,44% | +34,70% |
17/05 | Roche : le titre se distingue, Deutsche Bank en soutien | CF |
16/05 | Eli Lilly : collaboration de recherche avec Totus Medicines | CF |
Métier
- endocrinologie (57,7%) : produits pour le traitement de l'ostéoporose, du diabète et des problèmes de croissance ;
- oncologie (19,5%) ;
- maladies immunitaires (11,1%) ;
- neurologie (8,4%) : essentiellement médicaments destinés au traitement de la dépression et de la schizophrénie ;
- autres (3,3%).
La répartition géographique du CA est la suivante : Etats-Unis (63,9%), Europe (18,1%), Japon (4,9%), Chine (4,5%) et autres (8,6%).
Nombre d'employés: 43 000
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Human Pharmaceutical Products
100,0
%
| 28 541 | 100,0 % | 34 124 | 100,0 % | +19,56% |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
63,9
%
| 18 190 | 63,7 % | 21 791 | 63,9 % | +19,80% |
Europe
18,1
%
| 4 299 | 15,1 % | 6 175 | 18,1 % | +43,62% |
Other Foreign Countries
8,6
%
| 2 852 | 10,0 % | 2 946 | 8,6 % | +3,30% |
Japan
4,9
%
| 1 747 | 6,1 % | 1 673 | 4,9 % | -4,28% |
China
4,5
%
| 1 453 | 5,1 % | 1 540 | 4,5 % | +5,98% |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/01/96 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 01/01/01 |
Ruth Gimeno
PSD | President | - | - |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | - | 17/05/21 |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16/10/23 |
Alonzo Weems
CMP | Compliance Officer | - | 01/01/97 |
Chief Tech/Sci/R&D Officer | 50 | 01/01/18 | |
Corporate Officer/Principal | - | 01/01/05 | |
Ilya Yuffa
PRN | Corporate Officer/Principal | 49 | - |
Ronald DeMattos
PRN | Corporate Officer/Principal | - | - |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Director/Board Member | 63 | 25/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/04/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/01/05 |
Juan Luciano
BRD | Director/Board Member | 62 | 01/02/16 |
William Kaelin
BRD | Director/Board Member | 66 | 04/06/12 |
David Ricks
CEO | Chief Executive Officer | 56 | 01/01/96 |
Jamere Jackson
BRD | Director/Board Member | 54 | 01/10/16 |
Director/Board Member | 52 | 12/12/11 | |
Marschall Runge
BRD | Director/Board Member | 69 | 01/09/13 |
Karen Walker
BRD | Director/Board Member | 62 | 01/12/18 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 950 770 386 | 948 828 863 ( 99,80 %) | 365 000 ( 0,0384 %) | 99,80 % |
Participations
Nom | Actions | % | Valorisation |
---|---|---|---|
8 084 411 | 6,83% | 50 293 848 $ | |
PROQR THERAPEUTICS N.V. 16,55% | 13 371 562 | 16,55% | 26 208 262 $ |
4 000 000 | 9,40% | 20 920 000 $ | |
21 776 804 | 7,60% | 11 332 213 $ | |
AC IMMUNE SA 3,64% | 3 615 328 | 3,64% | 8 279 101 $ |
125 405 | 1,81% | 1 218 937 $ |
Coordonnées société
Sociétés du groupe
Nom | Catégorie et Secteur |
---|---|
ELI Lilly & Company (India) Pvt Ltd.
ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Eli Lilly Services India Pvt Ltd.
Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The company is based in Bangalore, India and was founded in 2015. |
Pharmaceuticals: Major
|
Eli Lilly Export SA (Switzerland)
Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide. |
Medical Distributors
|
Kinsale Financial Services
| |
Lilly Nederland Finance BV
Lilly Nederland Finance BV Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Nederland Finance BV leases non-financial intangible assets. The company is based in Utrecht, Netherlands. |
Miscellaneous Commercial Services
|
Eli Lilly SA
Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The company is based in Vernier, Switzerland. |
Pharmaceuticals: Major
|
Eli Lilly (Suisse) SA
| |
Lilly Global Nederland Holdings BV
Lilly Global Nederland Holdings BV Financial ConglomeratesFinance Part of Eli Lilly & Co., Lilly Global Nederland Holdings BV functions as an investment holding Dutch company. The company is based in Utrecht, Netherlands. |
Financial Conglomerates
|
Eli Lilly Vostok SA
|
Secteur
Ventes par région
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
+29,39% | 584 Md | |
-1,34% | 372 Md | |
+20,34% | 332 Md | |
+7,39% | 294 Md | |
+14,25% | 239 Md | |
-3,03% | 211 Md | |
+10,02% | 210 Md | |
+8,49% | 168 Md | |
-0,52% | 162 Md |
- Bourse
- Actions
- Action LLY
- Action LLY
- Société Eli Lilly and Company